top of page

PALTECH INNOVATION

MICROSCOPE

T2 diabetics and obese people have fewer Glucose receptors in the matrix of the portal vein. Those receptors are connected to the brain through the vagal nerve. If the brain has less information about glucose entry, it cannot stimulate insulin secretion by the pancreas to regulate glucose metabolism.

 

Paltech found a way to upregulate those receptors and recover the glucose regulation in the whole body.

All Videos

All Videos

Lire la vidéo

A BREAKTHROUGH FROM CURRENT PRACTICE

The Paltech solution will be a real game changer in the comprehensive T2 diabetes treatment. It could be used alone or in addition to medicines to help diminish doses to limit side effects.

TESTIMONIES

DIABETOLOGISTS AND SPECIALISTS CONFIRM PALTECH IS MUCH NEEDED

Professor @ CHU Grenoble

« GLP1-a doses are far from being physiological, explaining that many patients are struggling with secondary effects and ultimately give-up. A physiological treatment like your is very interesting »
bottom of page